Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T-cell leukemia homeobox protein 3 (TLX3) is a homeobox-containing nuclear transcription factor belonging to the HOX11 subfamily. It is normally involved in embryonic brain, nervous system, and T-cell development. Deregulated expression of TLX3, often due to chromosomal translocation, is implicated in the development of pediatric T-cell acute lymphoblastic leukemia (T-ALL). In T-ALL, TLX3 acts as an oncogenic driver by promoting the proliferation and differentiation arrest of immature T-cell precursors through direct and indirect regulation of various target genes and noncoding RNAs. TLX3 may also influence neuronal subtype specification during development by acting as a context-dependent transcriptional selector gene. Its aberrant expression is considered an important molecular marker and prognostic indicator in certain leukemias
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell leukemia homeobox protein 3 (TLX3).